CVS plans to make a major primary care play by the end of 2022 Amgen, on an M&A spree, inks $3.7B ChemoCentryx buyout to boost inflammatory disease presence Looking east, Sanofi pens 'pioneering' cancer drug partnership with China's Innovent Tandem lines up FDA review of new pint-sized insulin pump amid lower-than-expected sales HHS declares public health emergency over monkeypox Amarin suspends German sales force as Vascepa's European launch sputters Late to the CAR-T game, AstraZeneca quietly works on its own off-the-shelf therapies Glaukos nets FDA clearance for latest pressure-relieving glaucoma eye stent Lilly 'won't be discouraged' if others fail in Alzheimer's, neuroscience chief says CivicaScript bringing its first low-cost generic to market Thermo Fisher, plugging ahead on $650M bioprocessing upgrade, unveils $76M expansion at US site Virtual reality tech helps separate conjoined twins in Brazil Featured Story | By Heather Landi CVS plans to make a big move in primary care by investing or acquiring a provider by the end of this year. CVS is looking for providers with a strong management team and a robust tech stack. "Obviously, the ability to scale, given the size of the company that we are and a pathway to profitability," CVS CEO Karen Lynch said during the company's earnings call Wednesday. read more |
| |
|---|
|
Top Stories By Angus Liu Facing one of the biopharma industry’s steepest patent cliffs for the decade, Amgen has been on a shopping spree. The latest purchase? A $3.7 billion deal to acquire complement inhibitor developer ChemoCentryx. read more By James Waldron When it comes to global market expansion, many Big Pharmas have their eye on China—and clearly Sanofi is no exception. The French drugmaker has signed a cancer-focused deal with Suzhou-based Innovent, focused on developing and rolling out two of Sanofi’s oncology assets. read more By Andrea Park After stumbling a bit in the second quarter of the year, Tandem Diabetes is getting back on its feet, multi-quarter recovery plan already in place. read more By Robert King HHS Secretary Xavier Becerra declared a public health emergency on the monkeypox outbreak as cases in the U.S. surge past 6,000. read more By Zoey Becker Amarin has everything riding on Vascepa, its fish-oil derived heart drug. With the company’s sales presence in Germany suspended thanks to "unprecedented local market conditions,” Amarin finds itself in a tough spot as it wages on with the launch. read more By James Waldron While AstraZeneca may be a major player in the oncology space, the company has been noticeably absent as the first wave of CAR-T therapies hit the market over the past five years. But movement is happening behind the scenes. read more By Conor Hale The agency's green light opens up the use of Glaukos’ iStent through its own, standalone procedure—giving eye surgeons a greater range of options to treat elevated intraocular pressure and help prevent loss of vision. The company's prior versions of iStent could only be deployed while patients were already undergoing surgery to replace a cataract lens. read more By Annalee Armstrong Eli Lilly "won't be discouraged" if its Alzheimer's competitors flunk their critical tests, neuroscience chief Anne White has declared. The senior VP took the firm stance as Lilly announced that donanemab has been accepted for a priority review by the FDA in early onset Alzheimer's under the accelerated review pathway. read more By Paige Minemyer The public benefits company and sister to Civica Rx is making its first generic available: 250mg abiraterone acetate tablets. read more By Fraiser Kansteiner Thermo Fisher has completed an expansion at its dry powder media manufacturing plant in Grand Island, New York, creating “redundant capacity” and expanding the site’s production arsenal to include technology and materials used in the development and commercial production of new vaccines and biologic drugs. read more By Andrea Park The life-saving potential of VR is now on full display, as physicians in Brazil and the U.K. reported this week the success of a VR-guided surgery to separate twins who were joined at the skull. read more Resources Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. |
